[go: up one dir, main page]

DE3782378D1 - Dihydropyridinderivate und deren pharmazeutische zusammensetzungen. - Google Patents

Dihydropyridinderivate und deren pharmazeutische zusammensetzungen.

Info

Publication number
DE3782378D1
DE3782378D1 DE8787112302T DE3782378T DE3782378D1 DE 3782378 D1 DE3782378 D1 DE 3782378D1 DE 8787112302 T DE8787112302 T DE 8787112302T DE 3782378 T DE3782378 T DE 3782378T DE 3782378 D1 DE3782378 D1 DE 3782378D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
dihydropyridine derivatives
dihydropyridine
derivatives
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787112302T
Other languages
English (en)
Other versions
DE3782378T2 (de
Inventor
Atsuyuki Ashimori
Nishi-Iru Ono
Yoshihisa Inoue
Chikara Fukaya
Kazumasa Yokoyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Green Cross Corp Japan
Green Cross Corp Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan, Green Cross Corp Korea filed Critical Green Cross Corp Japan
Application granted granted Critical
Publication of DE3782378D1 publication Critical patent/DE3782378D1/de
Publication of DE3782378T2 publication Critical patent/DE3782378T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE8787112302T 1986-08-27 1987-08-25 Dihydropyridinderivate und deren pharmazeutische zusammensetzungen. Expired - Fee Related DE3782378T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP61200849 1986-08-27
JP25307786 1986-10-23

Publications (2)

Publication Number Publication Date
DE3782378D1 true DE3782378D1 (de) 1992-12-03
DE3782378T2 DE3782378T2 (de) 1993-03-11

Family

ID=26512428

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787112302T Expired - Fee Related DE3782378T2 (de) 1986-08-27 1987-08-25 Dihydropyridinderivate und deren pharmazeutische zusammensetzungen.

Country Status (5)

Country Link
EP (1) EP0257616B1 (de)
JP (1) JPH0686429B2 (de)
KR (1) KR950003923B1 (de)
DE (1) DE3782378T2 (de)
ES (1) ES2046189T3 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0725750B2 (ja) * 1987-12-18 1995-03-22 富士レビオ株式会社 １，４‐ジヒドロピリジン誘導体
ES2143453T3 (es) * 1988-05-19 2000-05-16 Yoshitomi Pharmaceutical Uso de derivados de dihidropiridina para la profilaxis o el tratamiento de trastornos de la circulacion cerebral.
US5286869A (en) * 1988-12-15 1994-02-15 Fujirebio Kabushiki Kaisha 1,4-dihydropyridine derivatives
JP2838282B2 (ja) * 1988-12-29 1998-12-16 吉富製薬株式会社 血管攣縮治療剤
JPH03141257A (ja) * 1989-10-26 1991-06-17 Green Cross Corp:The ジヒドロピリジン誘導体
DK0448091T3 (da) * 1990-03-23 1999-05-03 Yoshitomi Pharmaceutical Farmaceutisk præparat indeholdende et i ringe grad vandopløseligt medikament
DE69132927T2 (de) * 1990-06-25 2002-10-02 Mitsubishi Pharma Corp., Osaka Verwendung von Dihydropyridinen in kardiotonischen pharmazeutischen Zusammensetzungen
CA2138297A1 (en) * 1993-04-19 1994-10-27 Yoshitomi Pharmaceutical Industries Ltd. Novel pharmaceutical use of dihydropyridine derivative
CA2147762A1 (en) * 1993-08-25 1995-03-02 Hiroshi Shinyama Circulatory disorder improving agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2935451A1 (de) * 1979-09-01 1981-03-19 Bayer Ag, 5090 Leverkusen Optisch aktive 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arneimittel
WO1983003249A1 (en) * 1982-03-17 1983-09-29 Yoshitomi Pharmaceutical 1,4-dihydropyridine-3,5-dicarboxylate derivatives
DE3377352D1 (en) * 1982-06-03 1988-08-18 Pierrel Spa Dihydropyridines with an antagonistic activity to calcium, process for their preparation, and pharmaceutical compositions containing them
IL77843A (en) * 1985-02-11 1989-07-31 Syntex Inc Dihydropyridine derivatives,process and novel intermediates for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
DE3782378T2 (de) 1993-03-11
ES2046189T3 (es) 1994-02-01
KR950003923B1 (ko) 1995-04-20
EP0257616B1 (de) 1992-10-28
KR880002828A (ko) 1988-05-11
EP0257616A2 (de) 1988-03-02
JPH0686429B2 (ja) 1994-11-02
JPS63225356A (ja) 1988-09-20
EP0257616A3 (en) 1989-01-11

Similar Documents

Publication Publication Date Title
DE69015842D1 (de) Nicotinsäurederivate und diese enthaltende pharmazeutische Zusammensetzungen.
DE3486441D1 (de) 3-Hydroxypyrid-4-one und pharmazeutische Zusammensetzungen
DE10199066I1 (de) Pharmazeutische Zusammensetzung
DE69014351D1 (de) Pyridincarbonsäureamid-Derivate und diese enthaltende pharmazeutische Zusammensetzungen.
DE122004000023I2 (de) Pharmazeutische Zusammensetzung
NL300136I2 (nl) Farmacologisch actieve catecholderivaten en samenstellingen ervan.
FR2636532B1 (fr) Compositions pharmaceutiques
NZ222030A (en) Substituted imidazo-(5,4-g (3,1 benzoxaminone derivatives and pharmaceutical compositions
DE3879811D1 (de) Pharmazeutische zusammensetzung und ihre verwendung.
DE3682083D1 (de) Pharmazeutische zusammensetzungen.
DE3583765D1 (de) Hydantoinderivate und diese enthaltende pharmazeutische zusammensetzungen.
FI943645L (fi) Uusia bakkatiini-III ja 10-deasetyylibakkatiini-III-johdannaisia, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
DE69024843D1 (de) Rhodanin-Derivate und pharmazeutische Zusammensetzungen
DE3782378D1 (de) Dihydropyridinderivate und deren pharmazeutische zusammensetzungen.
MC1878A1 (fr) Compositions pharmaceutiques
DE3852332D1 (de) 4-Thiochinazolin-Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammenstellungen.
KR900700452A (ko) 테트라히드로피리딘 유도체, 그를 함유하는 약학 조성물 및 그의 제조방법
DE3578597D1 (de) 4-phenylphthalazin-derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
DE68909555D1 (de) Pyridylketoximether-verbindung und diese enthaltende pharmazeutische zusammensetzung.
PT84339A (pt) 1,6-naphthyridine derivatives process for the preparation thereof and pharmaceutical compositions containing them
NZ216555A (en) 1,4-dihydropyridine derivatives and pharmaceutical compositions
DE3586445D1 (de) Kondensierte benzo-laktam-verbindungen und deren pharmazeutische zusammensetzungen.
ATA133288A (de) Pharmazeutische zusammensetzung
DE3871159D1 (de) Pharmazeutische und tieraerztliche zusammensetzungen.
NZ215083A (en) 1,4-dihydropyridine derivatives and pharmaceutical compositions

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD., OSAKA,

8327 Change in the person/name/address of the patent owner

Owner name: WELFIDE CORP., OSAKA, JP

8327 Change in the person/name/address of the patent owner

Owner name: MITSUBISHI PHARMA CORP., OSAKA, JP

8339 Ceased/non-payment of the annual fee